Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates
Perinatal asphyxia and neonatal encephalopathy remain major causes of neonatal mortality, despite the improved availability of diagnostic and therapeutic tools, contributing to neurological and intellectual disabilities worldwide. An approach using a combination of clinical data, neuroimaging, and b...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Bioengineering |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2306-5354/9/10/498 |
| _version_ | 1797475212316377088 |
|---|---|
| author | Girish Kumar Rasineni Nalinikanta Panigrahy Subha Narayan Rath Madhurarekha Chinnaboina Ramesh Konanki Dinesh Kumar Chirla Srinivas Madduri |
| author_facet | Girish Kumar Rasineni Nalinikanta Panigrahy Subha Narayan Rath Madhurarekha Chinnaboina Ramesh Konanki Dinesh Kumar Chirla Srinivas Madduri |
| author_sort | Girish Kumar Rasineni |
| collection | DOAJ |
| description | Perinatal asphyxia and neonatal encephalopathy remain major causes of neonatal mortality, despite the improved availability of diagnostic and therapeutic tools, contributing to neurological and intellectual disabilities worldwide. An approach using a combination of clinical data, neuroimaging, and biochemical parameters is the current strategy towards the improved diagnosis and prognosis of the outcome in neonatal hypoxic–ischemic encephalopathy (HIE) using bioengineering methods. Traditional biomarkers are of little use in this multifactorial and variable phenotype-presenting clinical condition. Novel systems of biology-based “omics” approaches (genomics, transcriptome proteomics, and metabolomics) may help to identify biomarkers associated with brain and other tissue injuries, predicting the disease severity in HIE. Biomarker studies using omics technologies will likely be a key feature of future neuroprotective treatment methods and will help to assess the successful treatment and long-term efficacy of the intervention. This article reviews the roles of different omics as biomarkers of HIE and outlines the existing knowledge of our current understanding of the clinical use of different omics molecules as novel neonatal brain injury biomarkers, which may lead to improved interventions related to the diagnostic and therapeutic aspects of HIE. |
| first_indexed | 2024-03-09T20:41:58Z |
| format | Article |
| id | doaj.art-8e2c66055c054d028265e3c53fe9381f |
| institution | Directory Open Access Journal |
| issn | 2306-5354 |
| language | English |
| last_indexed | 2024-03-09T20:41:58Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Bioengineering |
| spelling | doaj.art-8e2c66055c054d028265e3c53fe9381f2023-11-23T22:56:55ZengMDPI AGBioengineering2306-53542022-09-0191049810.3390/bioengineering9100498Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in NeonatesGirish Kumar Rasineni0Nalinikanta Panigrahy1Subha Narayan Rath2Madhurarekha Chinnaboina3Ramesh Konanki4Dinesh Kumar Chirla5Srinivas Madduri6LCMS Division, Tenet Medcorp Pvt. Ltd., 54 Kineta Towers Road No 3, Banjara Hills, Hyderabad 500034, IndiaDepartment of Neonatology, Rainbow Children’s Hospital, Hyderabad 500034, IndiaRegenerative Medicine and Stem Cell Laboratory, Department of Biomedical Engineering, Indian Institute of Technology Hyderabad, Telangana 502284, IndiaLCMS Division, Tenet Medcorp Pvt. Ltd., 54 Kineta Towers Road No 3, Banjara Hills, Hyderabad 500034, IndiaDepartment of Pediatric Neurology, Rainbow Children’s Hospital, Hyderabad 500034, IndiaDepartment of Neonatology, Rainbow Children’s Hospital, Hyderabad 500034, IndiaBioengineering and Regenerative Medicine, Department of Biomedical Engineering, University of Basel, University Hospital Basel, 4001 Basel, SwitzerlandPerinatal asphyxia and neonatal encephalopathy remain major causes of neonatal mortality, despite the improved availability of diagnostic and therapeutic tools, contributing to neurological and intellectual disabilities worldwide. An approach using a combination of clinical data, neuroimaging, and biochemical parameters is the current strategy towards the improved diagnosis and prognosis of the outcome in neonatal hypoxic–ischemic encephalopathy (HIE) using bioengineering methods. Traditional biomarkers are of little use in this multifactorial and variable phenotype-presenting clinical condition. Novel systems of biology-based “omics” approaches (genomics, transcriptome proteomics, and metabolomics) may help to identify biomarkers associated with brain and other tissue injuries, predicting the disease severity in HIE. Biomarker studies using omics technologies will likely be a key feature of future neuroprotective treatment methods and will help to assess the successful treatment and long-term efficacy of the intervention. This article reviews the roles of different omics as biomarkers of HIE and outlines the existing knowledge of our current understanding of the clinical use of different omics molecules as novel neonatal brain injury biomarkers, which may lead to improved interventions related to the diagnostic and therapeutic aspects of HIE.https://www.mdpi.com/2306-5354/9/10/498hypoxic–ischemic encephalopathygenomicsproteomicsmetabolomicsbiomarkersomics |
| spellingShingle | Girish Kumar Rasineni Nalinikanta Panigrahy Subha Narayan Rath Madhurarekha Chinnaboina Ramesh Konanki Dinesh Kumar Chirla Srinivas Madduri Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates Bioengineering hypoxic–ischemic encephalopathy genomics proteomics metabolomics biomarkers omics |
| title | Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates |
| title_full | Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates |
| title_fullStr | Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates |
| title_full_unstemmed | Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates |
| title_short | Diagnostic and Therapeutic Roles of the “Omics” in Hypoxic–Ischemic Encephalopathy in Neonates |
| title_sort | diagnostic and therapeutic roles of the omics in hypoxic ischemic encephalopathy in neonates |
| topic | hypoxic–ischemic encephalopathy genomics proteomics metabolomics biomarkers omics |
| url | https://www.mdpi.com/2306-5354/9/10/498 |
| work_keys_str_mv | AT girishkumarrasineni diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates AT nalinikantapanigrahy diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates AT subhanarayanrath diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates AT madhurarekhachinnaboina diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates AT rameshkonanki diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates AT dineshkumarchirla diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates AT srinivasmadduri diagnosticandtherapeuticrolesoftheomicsinhypoxicischemicencephalopathyinneonates |